Clinical trials · New York, NY
Central Nervous System Diseases clinical trials in New York
We’re tracking 23 recruiting central nervous system diseases studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
New York, New YorkAges 18 years+ - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
New York, New YorkAges 18 years+ - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
New York, New YorkAges 18–75 - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
New York, New YorkAges 3–22 - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
New York, New YorkAges 1–21 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
New York, New YorkAges 18–75 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
New York, New YorkAges 12 months–25 years - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
New York, New YorkAges Up to 25 years - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
New York, New YorkAges 3–29 - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
New York, New YorkAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
New York, New YorkAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
New York, New YorkAges 18 years+ - NCT07082868RecruitingPhase 1
Study of epcoritamab and ibrutinib for central nervous system lymphoma
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
New York, New YorkAges 18 years+ - NCT07539441RecruitingPhase 1/Phase 2
Mirdametinib for brain and nervous system tumors
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
New York, New YorkAges 18 years+ - NCT07137494RecruitingPhase 1
CAR T-cell therapy for CNS lymphoma
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
New York, New YorkAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
New York, New YorkAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
New York, New YorkAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
New York, New YorkAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
New York, New YorkAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Hackensack, New JerseyAges 18 years+ - NCT05725499Recruiting
Check if skin stimulation lowers blood pressure drops after spinal injury
This study tests a skin “stimulation” treatment to see if it helps stabilize blood pressure in people with spinal cord injury who get low blood pressure when sitting up. If you often have dizziness, faintness, or low readings after changing positions, this trial may help find safer ways to manage it.
West Orange, New JerseyAges 18–75 - NCT05731986Recruiting
Skin nerve stimulation to raise blood pressure after spinal injury
This study tests whether a device that delivers mild electrical stimulation through the skin can improve low blood pressure after an acute spinal cord injury. It may help reduce episodes of dizziness or faint-feeling caused by blood pressure dropping when you sit up.
West Orange, New JerseyAges 18–75 - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+
Hear when a new Central Nervous System Diseases trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Central Nervous System Diseases trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting central nervous system diseases studies listed above.
- Memorial Sloan Kettering Cancer Center · 15 studies
- Columbia University Irving Medical Center · 9 studies
- Rutgers Cancer Institute of New Jersey · 6 studies
- Hackensack University Medical Center · 5 studies
- NYU Langone Health · 5 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Montefiore Medical Center · 4 studies
- New York Medical College · 4 studies
What taking part in a central nervous system diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there central nervous system diseases clinical trials near New York?
- Yes. We're currently tracking 23 recruiting central nervous system diseases studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a central nervous system diseases study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a central nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New central nervous system diseases studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.